Watch hVIVO’s July 2024 Capital Markets Day here
At hVIVO, we play an important role in improving global health by supporting the clinical development of medicinal products, especially infectious and respiratory disease products, through human challenge trials. As a growing organization, we recognise the importance of continually improving our governance and prioritising social and environmental concerns in all our work.
We are committed to operating as a responsible business; and as part of this commitment, we are currently assessing the Company’s environmental, social and governance protocols and policies. hVIVO has established a cross business working group, called the ESG Group, which focuses on identifying risks and opportunities related to climate change and other social and governance topics. Yamin ‘Mo’ Khan leads the ESG Group and report directly to the Audit and Risk Committee. The ESG Group consists of representatives from various areas of our business and report to the to Audit and Risk Committee, which is responsible for reviewing the Company’s ESG reporting and recommending it to the Board.
Infectious diseases are a significant burden to global health, and hVIVO plays an important role in helping to bring vital vaccines & antivirals to the market faster than otherwise possible, using human clinical trials.
Our employees are the key to our success; in line with our Diversity & Equal Opportunities Policy, we are focussed on building a strong corporate culture, with diversity and equality at the centre.
We place participants and patients at the heart of our business and carefully safeguard their wellbeing in clinical research and data protection and ensure that their feedback is heard so that we can continually improve our processes.
We believe in giving back to our community and those in need. To achieve this goal, we have implemented numerous new initiatives hVIVO’s Volunteering Policy and work towards the implementation of new initiatives such as our Charitable Donations Policy and Community Engagement Programme.
We are committed to reducing our impact on the environment; as part of our Environmental Policy, we ensure all energy consumption is monitored and are working towards implementing measurable metrics and targets to help minimise our carbon footprint.
We operate our trials in the highest quality safety, regulatory and ethical environment. We are committed to honesty, transparency and quality which is embedded in our Clinical Governance Policy and Business Code of Ethics.
Yamin 'Mo' Khan
CEO & Head of the ESG Group
“Our ESG values underscore our dedication to advancing health and research, fostering a culture of equality, diversity and inclusion, and prioritising ethical business practices. These values guide our initiatives across social and community investment, sustainability practices, and our support for participants and patients.
Aligned with the United Nations Sustainable Development Goals, we focus our efforts on key areas relevant to our industry. We actively contribute to global health challenges by supporting the development of vital medicines to tackle infectious diseases. Our commitment extends to neglected tropical diseases, where our expanded portfolio addresses critical medical needs.
We prioritise our staff’s well-being and development, fostering an inclusive workplace culture supported by our policies, initiatives, and events which reflect our dedication to creating a supportive and collaborative environment.
Furthermore, our social and community investment initiatives demonstrate our commitment to giving back and creating meaningful impacts beyond our corporate borders. Operating sustainably is fundamental to our business model. We are committed to effective environmental management, minimizing our environmental footprint, and are on a path towards implementing ISO14001 principles. ISO14001 is an internationally recognised standard for environmental management systems (EMS). It provides a framework for organizations to design and implement an EMS, and continually improve their environmental performance. Our streamlined energy and carbon reporting, waste reduction initiatives, and responsible food supply practices all form part of our commitment to environmental stewardship.
Ethical and compliant business practices are non-negotiable for us. We uphold the highest standards of corporate governance, ethical conduct, and transparency across all our operations. Our robust quality systems, adherence to regulatory standards, and commitment to participant safety underscore our dedication to ethical clinical research.
We made excellent progress in our ESG efforts in 2023 and we will continue to innovate, collaborate, and drive positive change in 2024 and beyond, ensuring that our operations remain aligned with our core values and contribute meaningfully to a more sustainable future for all.”
